Published in Int J Womens Health on January 11, 2014
Women-specific factors to consider in risk, diagnosis and treatment of cardiovascular disease. Womens Health (Lond Engl) (2015) 0.82
Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis. Syst Rev (2016) 0.78
HDL-Associated Paraoxonase 1 as a Bridge between Postmenopausal Osteoporosis and Cardiovascular Disease. Chonnam Med J (2014) 0.76
Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends. Chem Res Toxicol (2016) 0.75
A novel mechanism of non-feminizing estrogens in neuroprotection. Exp Gerontol (2016) 0.75
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med (1995) 11.08
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women's health across the nation. Am J Public Health (2006) 4.51
Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J Natl Cancer Inst (2011) 4.14
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
The 2012 hormone therapy position statement of: The North American Menopause Society. Menopause (2012) 4.04
Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol (2000) 3.94
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation (2007) 3.17
Bioidentical hormone therapy: a review. Menopause (2004) 2.97
Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial. Diabetologia (2004) 2.63
Premature menopause or early menopause: long-term health consequences. Maturitas (2009) 2.33
Recommendations for the management of postmenopausal vaginal atrophy. Climacteric (2010) 2.28
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
Estrogen and/or androgen replacement therapy and cognitive functioning in surgically menopausal women. Psychoneuroendocrinology (1988) 1.99
Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric (2013) 1.94
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 1.88
Premature menopause or early menopause and risk of ischemic stroke. Menopause (2012) 1.84
Vulvovaginal atrophy. Mayo Clin Proc (2010) 1.81
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ (2008) 1.78
Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev (2009) 1.63
Gradual discontinuation of hormone therapy does not prevent the reappearance of climacteric symptoms: a randomized prospective study. Menopause (2006) 1.59
Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat (2007) 1.55
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause (2007) 1.51
Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res (2010) 1.48
Sleep in menopause: differential effects of two forms of hormone replacement therapy. Menopause (2001) 1.48
Increased risk of stroke in hypertensive women using hormone therapy: analyses based on the Danish Nurse Study. Arch Neurol (2003) 1.45
Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med (2006) 1.40
Micronized progesterone: clinical indications and comparison with current treatments. Fertil Steril (1999) 1.40
NIH State-of-the-Science Conference Statement on management of menopause-related symptoms. NIH Consens State Sci Statements (2007) 1.38
Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ (2010) 1.32
Estrogen treatment after ovariectomy protects against fatty liver and may improve pathway-selective insulin resistance. Diabetes (2012) 1.28
Sleep symptoms during the menopausal transition and early postmenopause: observations from the Seattle Midlife Women's Health Study. Sleep (2010) 1.26
Associations of depression with the transition to menopause. Menopause (2010) 1.25
The 2013 British Menopause Society & Women's Health Concern recommendations on hormone replacement therapy. Menopause Int (2013) 1.17
The effect of hormone replacement therapy on body composition, body fat distribution, and insulin sensitivity in menopausal women: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab (2005) 1.15
Vaginal health in the United States: results from the Vaginal Health: Insights, Views & Attitudes survey. Menopause (2013) 1.14
Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med (1985) 1.10
Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause (2013) 1.08
Global Consensus Statement on menopausal hormone therapy. Maturitas (2013) 1.05
Timing hypothesis for postmenopausal hormone therapy: its origin, current status, and future. Menopause (2013) 1.04
Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause (2011) 1.03
Estrogens, estrogen receptors, and female cognitive aging: the impact of timing. Horm Behav (2012) 1.00
Increased mortality for neurological and mental diseases following early bilateral oophorectomy. Neuroepidemiology (2009) 0.97
Oral micronized progesterone. Clin Ther (1999) 0.96
Androgen therapy in women. Eur J Endocrinol (2006) 0.95
Can depression be a menopause-associated risk? BMC Med (2010) 0.94
The timing hypothesis for coronary heart disease prevention with hormone therapy: past, present and future in perspective. Climacteric (2012) 0.91
Hormone replacement therapy and the association with coronary heart disease and overall mortality: clinical application of the timing hypothesis. J Steroid Biochem Mol Biol (2013) 0.89
Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab (2013) 0.88
The levonorgestrel intrauterine system for use in peri- and postmenopausal women. Contraception (2007) 0.87
Female sexual health consensus clinical guidelines. J Obstet Gynaecol Can (2012) 0.86
What's new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric (2012) 0.86
A decade after the Women's Health Initiative--the experts do agree. Fertil Steril (2012) 0.86
Oral micronized progesterone. Bioavailability pharmacokinetics, pharmacological and therapeutic implications--a review. Contraception (1987) 0.85
Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt) (2011) 0.84
Low-dose estrogen therapy for menopausal women: a review of efficacy and safety. J Womens Health (Larchmt) (2003) 0.84
The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Maturitas (1997) 0.84
Postmenopausal hormone therapy before and after the women's health initiative study: what consequences? Ann Med (2004) 0.83
Hormone therapy and the risk of stroke: perspectives 10 years after the Women's Health Initiative trials. Climacteric (2012) 0.82
Considerations in the choice of oral vs. transdermal hormone therapy: a review. J Reprod Med (2004) 0.81
Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas (2002) 0.79
An update on menopausal hormone replacement therapy in women and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes (2013) 0.79
Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians. J Am Board Fam Med (2011) 0.78
Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication. Dan Med Bull (2006) 0.77
Ultra-low-dose vaginal estrogen tablets for the treatment of postmenopausal vaginal atrophy. Climacteric (2013) 0.76
Is timing everything? New insights into why the effect of estrogen therapy on memory might be age dependent. Endocrinology (2013) 0.76
Vaginal progesterone in menopause: Crinone 4% in cyclical and constant combined regimens. Hum Reprod (2000) 0.76
Endometrial cancer after endometrial ablation: systematic review of medical literature. J Minim Invasive Gynecol (2011) 0.76